Thoracic Research and Practice
Original Article

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib

1.

Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey

2.

Department of Medical Oncology, Bakırçay University, İzmir, Turkey

3.

Department of Medical Oncology, Ege University, İzmir, Turkey

4.

Department of Nuclear Medicine, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey

Thorac Res Pract 2023; 24: 180-185
DOI: 10.5152/ThoracResPract.2023.22200
Read: 783 Downloads: 436 Published: 01 July 2023

OBJECTIVE: Alectinib has a much better central nervous system transmission than crizotinib in patients diagnosed with anaplastic lymphoma kinase mutation-positive nonsmall cell lung carcinoma. We aimed to investigate alectinib’s efficacy in the treatment and its place in the first-line treatment and report our real-life data.

MATERIAL AND METHODS: The data of 38 patients who were diagnosed with anaplastic lymphoma kinase-positive nonsmall cell lung carcinoma in our clinic between 2016 and 2021, who did not receive any treatment before were retrospectively analyzed.

RESULTS: Of the 19 patients who received alectinib, 14 had multiple, and 6 had pretreatment brain metastases. No newly emerging brain metastases were detected during the treatment period. The progression-free survival of patients was 23.5 ± 4.2 months, and overall survival was 24.6 ± 4.1 months. Progression was observed in 10 (52.6%) patients. Of the 19 patients who received crizotinib, 7 had multiple metastases, and brain metastases were detected in 1 patient before treatment and 6 patients during the treatment period. Progression-free survival of crizotinib patients was 17.1 ± 4.8 months and their overall survival was 26.5 ± 6.1 months. Progression was observed in 17 (89.5%) patients. The second line of alectinib could be given to 8 of these patients. Overall survival after second-line treatment of alectinib was 18.2 ± 7.0 months. Overall survival of the patients who could not receive second-line treatment of alectinib was 4.0 ± 2.0 months.

CONCLUSION: The progression rate was lower in alectinib than the crizotinib patients, although there were more patients with multiple metastases and brain metastases in the alectinib arm.

Cite this article as: Katgi N, Çimen P, Akyol M, Gürsoy P, Agüloğlu N. Comparison of alectinib/crizotinib data in first-line therapy in patients with anaplastic lymphomakinase-positive nonsmall cell lung carcinoma with poor prognostic features for alectinib. Thorac Res Pract. 2023;24(4):180-185.

Files
EISSN 2979-9139